阴道炎治疗市场依治疗方法、给药途径、产品类型、通路和最终用户群划分－2025-2032年全球预测

预计到 2032 年，阴道炎治疗市场将成长至 56.9 亿美元，复合年增长率为 9.44%。

主要市场统计数据
基准年 2024	27.6亿美元
预计年份：2025年	30.2亿美元
预测年份：2032年	56.9亿美元
复合年增长率 (%)	9.44%

这份简明扼要而又引人入胜的阴道炎治疗概述，清楚地阐明了治疗的紧迫性、尚未满足的临床需求以及相关人员的战略重点。

阴道炎一直是临床医生、支付方和产品开发商的焦点，因为它兼具常见的临床需求、复杂的诊断难度和不断变化的患者偏好。以下概述提供了医疗保健和生命科学领域相关人员在製定产品组合决策、临床开发重点和商业化策略时应考虑的临床背景和策略因素。

科学突破、病人期望以及医疗服务模式的转变，正以变革性的力量重塑阴道炎的治疗模式。

由于科学、商业和患者主导力量的融合，阴道炎的治疗格局正在经历一场变革。微生物组学和标靶抗真菌药物的进步正在拓展治疗手段，使研发人员能够摆脱「一刀切」的产品模式，转而开发针对特定病因和復发因素的干预措施。

预测美国关税在2025年对阴道炎治疗药物的供应链、价格趋势和临床可及性的累积影响

主要经济体征收的关税会对药品采购、生产和分销产生连锁反应，而美国政策预计将在2025年进行调整，因此，整个阴道炎治疗价值链都需要进行周密的战略规划。无论是对原料、成品製剂或包装组件征收关税，进口关税的变化都会影响采购决策、供应商谈判以及生产基地的地理布局。为此，各组织应预见供应商集中度的变化，并考虑采用多元化采购策略，以降低对单一国家的依赖风险。

提供关于治疗领域、给药途径、产品类型、分销渠道和人口统计群体等方面的可操作细分信息，以指导临床和商业性决策。

阴道炎治疗有效细分是商业和临床策略的基础，因为它界定了临床差异化和商业性机会的交会点。治疗细分区分了抗真菌疗法和益生菌疗法。在抗霉菌疗法中，又可分为Azole和Polyenes，Azole可进一步细分为Clotrimazole、Fluconazole和Miconazole等关键药物，而Polyenes则包括双性杀霉素B和製霉菌素。这种治疗方法细分至关重要，因为不同类别的药物在动态、復发情况和抗药性方面存在差异，从而影响临床定位和实证医学证据的需求。

从美洲、欧洲、中东和非洲以及亚太地区的战略视角出发，确定市场进入和供应优先事项。

区域趋势对阴道炎治疗市场的监管管道、供应链物流和患者就医策略有显着影响。美洲地区拥有多元化的支付体系和分销模式，涵盖了私人和公共采购机制，数位化医疗的普及率也在稳步提升。这些趋势有利于那些展现出明显临床差异化优势和更高患者依从性的产品，并奖励那些能够同时利用机构采购和零售/线上管道的製造商。

不断发展的阴道炎治疗市场中製造商、创新者和经销商的竞争及企业策略

目前，阴道炎治疗市场的竞争优势取决于临床差异化、配方创新和分销灵活性的综合作用。拥有丰富产品系列的成熟製造商往往利用规模经济来确保分销管道畅通和快速补货。同时，小规模的创新企业通常将临床差异化、新颖的作用机制和更佳的耐受性视为竞争优势。企业面临的策略挑战包括：投资于强有力的对比研究，以证明其产品能够降低復发率并改善患者报告的疗效；以及开发能够提高患者依从性和保护消费者隐私的包装和剂型。

为阴道炎治疗领域的行业领导者提供具有重大影响的策略建议，以加快患者疗效、优化产品组合併确保供应链的韧性。

我们鼓励产业领导者制定切实可行的行动计划，将洞察转化为临床、商业和营运领域可衡量的成果。首先，应优先发展能够产生直接临床结果和復发数据的研发管道，因为这些终点指标正日益影响支付方和临床医生的决策。此外，还应补充以患者为中心的证据，例如依从性、生活品质指标和真实世界中的復发预防数据，以增强您的价值提案。

调查方法进行了全面的概述，解释了治疗分析的资料来源、分析框架、检验过程和局限性。

本报告的研究基于三角调查方法，该方法结合了对关键相关利益者的访谈、对同行评审临床文献的系统性回顾、对监管指南的分析以及对分销和供应链指标的评估。主要资料来源包括对临床医生、处方集管理人员、采购人员和产品开发专业人员的结构化访谈，以收集有关临床需求、证据预期和获取挑战的第一手资讯。次要分析整合了临床试验结果、指引更新和安全性数据，以确保临床声明有已发表的证据支持。

整合策略洞察和视角，将临床、监管和商业性知识转化为相关人员可执行的优先事项。

这个总体方案整合了临床、监管和商业性的洞察，为关注阴道炎治疗的相关人员制定了一套连贯的优先事项。无论治疗类别或给药途径为何，关键挑战显而易见：能够大幅降低復发率、提高耐受性并符合患者偏好的治疗方法最有可能获得持续推广。实现这一目标需要一种综合方法，将严谨的临床计画与真实世界证据收集以及支持患者依从性和监测的数位互动策略相结合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 快速采用新一代分子诊断技术进行精准的阴道微生物组分析与标靶化治疗。
• 加强旨在恢復復发性阴道炎患者阴道健康菌丛的生物治疗产品研发管线
• 加大对硼酸和非抗生素硼酸酯疗法在生物膜破坏方面的投资
• 非处方抗真菌凝胶配方，添加了黏膜附着性聚合物，以提高患者依从性和疗效。
• 透过整合远端医疗和数位症状追踪应用程序，实现阴道炎治疗管道和结果的个人化
• 利用新一代定序技术对阴道微生物群进行定序和抗药性基因谱分析，以选择个人化治疗方案。
• 用于预防復发性细菌性阴道炎的非荷尔蒙微生物群修復产品获得加速监管核准
• 一项评估阴道微生物移植作为治疗难治性细菌性阴道炎替代疗法疗效的临床研究

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 阴道炎治疗市场：依治疗方法划分

• 抗真菌治疗
  • Azole
    • Clotrimazole
    • Fluconazole
    • Miconazole
  • Polyenes
    • 双性杀霉素B
    • 制霉菌素
• 益生菌疗法

9. 依给药途径分類的阴道炎治疗市场

• 阴道给药
  • 奶油
  • 凝胶
  • 栓剂
• 口服
  • 胶囊
  • 药片
• 外用药物
  • 奶油
  • 凝胶
  • 软膏

第十章 依产品类型分類的阴道炎治疗市场

• 非处方药
• 处方药

第十一章 按分销管道分類的阴道炎治疗市场

• 医院药房
• 网路药房
• 零售药房

第十二章 依最终用户细分市场分類的阴道炎治疗市场

• 停经后妇女
  • 46至60岁
  • 60岁或以上
• 闭经妇女
  • 18至25岁
  • 26至35岁
  • 36至45岁
• 孕妇

第十三章 各地区阴道炎治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 按组别分類的阴道炎治疗市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国阴道炎治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited

The Vaginitis Therapeutics Market is projected to grow by USD 5.69 billion at a CAGR of 9.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.76 billion
Estimated Year [2025]	USD 3.02 billion
Forecast Year [2032]	USD 5.69 billion
CAGR (%)	9.44%

A concise yet compelling overview of vaginitis therapeutics that frames urgency, clinical unmet needs, and strategic priorities for stakeholders

Vaginitis remains a focal point for clinicians, payers, and product developers because it intersects prevalent clinical need, diagnostic complexity, and a shifting patient preference landscape. The introduction below frames the clinical context and strategic drivers that should inform portfolio decisions, clinical development prioritization, and commercialization strategies for stakeholders across healthcare and life sciences.

Clinically, vaginitis encompasses a spectrum of etiologies that demand divergent therapeutic approaches, ranging from antifungal regimens to probiotic adjuncts aimed at restoring microbiome balance. Diagnostic ambiguity persists in many care pathways, complicating treatment selection and driving patient dissatisfaction. At the same time, advancements in formulation science and increasing acceptance of at-home care pathways have expanded the tactical options available to manufacturers and providers. These trends create both opportunities for differentiated product positioning and risks for commoditization if clinical value is not clearly articulated.

From a strategic perspective, the convergence of regulatory scrutiny, payer emphasis on cost-effectiveness, and digital health enablement is reshaping how therapies progress from concept to clinic. Commercial strategies must therefore integrate clinical evidence generation, real-world outcomes capture, and patient-centric access models to build sustainable adoption. In short, the field calls for an integrated approach that aligns therapeutic innovation with pragmatic deployment in diverse care settings.

Evolutionary forces reshaping the vaginitis treatment landscape through scientific breakthroughs, patient expectations, and shifts in care delivery models

The landscape for vaginitis therapeutics is undergoing transformative shifts driven by converging scientific, commercial, and patient-driven forces. Scientific advances in microbiome science and targeted antifungal pharmacology are broadening the therapeutic toolkit, enabling developers to move beyond one-size-fits-all products toward interventions that address specific etiologies and recurrence drivers.

Concurrently, patients are exerting greater influence over care choices, favoring discreet, convenient, and evidence-backed options that fit into their daily routines. This has accelerated demand for oral and intravaginal formats that deliver rapid symptom relief while fitting home-based treatment paradigms. Digital diagnostics and telehealth are also reshaping early triage and treatment initiation, reducing barriers to care but raising expectations for integrated digital support and clear evidence of clinical benefit.

Commercial dynamics are evolving in parallel: payers and procurement stakeholders increasingly prioritize therapeutic value demonstrated through outcomes and reduced recurrence rates. Manufacturers that invest in robust post-market evidence, adherence support initiatives, and supply chain resilience will be better positioned to secure formulary access and provider endorsement. Taken together, these shifts signal a market that rewards targeted clinical differentiation, patient-centric delivery models, and data-driven value propositions.

Anticipating the cumulative implications of United States tariff actions in 2025 on supply chains, pricing dynamics, and clinical accessibility across vaginitis therapeutics

Tariff actions originating from major economies can have cascading effects across pharmaceutical sourcing, manufacturing, and distribution, and the United States policy adjustments anticipated in 2025 warrant careful strategic planning across the vaginitis therapeutics value chain. Changes in import duties, whether enacted on raw materials, finished dosage forms, or packaging components, can influence procurement decisions, supplier negotiations, and the geographic configuration of production footprints. In response, organizations should anticipate shifts in supplier concentration and consider dual-sourcing strategies to mitigate single-country exposure.

Price pressure may manifest differently across segments; products that are predominantly imported or rely on complex supply chains could see cost passthrough pressures that affect list prices, payer negotiations, and ultimately patient out-of-pocket costs. Moreover, tariff-induced cost variability can compress margins for commoditized therapeutics unless manufacturers proactively redesign supply chains, optimize formulation yields, or transition certain components to domestic production. Regulatory timelines and batch release processes must also be recalibrated when manufacturing relocations occur to prevent interruptions in product availability.

Beyond direct cost implications, tariffs can catalyze strategic responses such as increased vertical integration, regional manufacturing hubs, and greater emphasis on supplier partnerships that lock in long-term pricing and capacity. Stakeholders should therefore adopt scenario-based planning, stress-test procurement and distribution assumptions, and prioritize investments that enhance agility, cost visibility, and continuity of supply to reduce exposure to trade policy volatility.

Actionable segmentation intelligence on therapeutic classes, routes, product types, distribution channels, and demographic cohorts driving clinical and commercial decisions

Effective segmentation is foundational to commercial and clinical strategy in vaginitis therapeutics because it clarifies where clinical differentiation and commercial opportunities converge. Treatment type segmentation distinguishes antifungal therapies from probiotic approaches; within antifungal treatments there are class distinctions between azoles and polyenes, with azoles further segmented by dominant agents such as clotrimazole, fluconazole, and miconazole, while polyenes encompass amphotericin B and nystatin. This therapeutic granularity matters because pharmacodynamics, recurrence profiles, and resistance considerations differ across classes, shaping clinical positioning and evidence generation needs.

Route of administration is another pivotal segmentation axis. Intravaginal delivery subdivides into creams, gels, and suppositories, each offering distinct onset-of-action profiles, adherence implications, and patient preferences. Oral formulations are categorized into capsules and tablets, which present advantages in terms of systemic exposure and convenience but require different safety and labeling considerations. Topical preparations, including creams, gels, and ointments, serve unique roles in symptomatic relief and localized therapy and are evaluated differently by providers and patients.

Product type division between over-the-counter and prescription status impacts promotional approaches, regulatory obligations, and access pathways. Distribution channel segmentation spans hospital pharmacies, online pharmacies, and retail pharmacies, each with unique purchasing behaviors, formulary dynamics, and service expectations. Finally, end user demographic segmentation differentiates post-menopausal women, pre-menopausal women, and pregnant women; these cohorts are further stratified by age bands that influence prevalence, comorbidity profiles, and tolerability concerns. Integrating these segmentation dimensions enables stakeholders to design targeted clinical trials, tailor messaging to specific care settings, and prioritize channels that optimize adoption and adherence.

Regionally differentiated strategic outlooks for the Americas, Europe Middle East and Africa, and Asia-Pacific that inform market access and supply priorities

Regional dynamics exert a profound influence on regulatory pathways, supply logistics, and patient access strategies across the vaginitis therapeutics landscape. The Americas region combines diverse payer systems and distribution models, where private and public procurement mechanisms coexist and where digital care adoption is steadily increasing. These dynamics favor products that demonstrate a clear clinical differentiator or improved adherence, and they reward manufacturers that can navigate both institutional purchasing and retail/online channels.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways requires adaptive market entry playbooks. Some markets demand extensive clinical comparators and health economics evidence, while others prioritize cost-effective, easily deployable solutions. Supply chain complexity and variable cold chain infrastructures in certain geographies also influence product design and packaging decisions. In contrast, the Asia-Pacific region is characterized by rapid adoption of digital health platforms, high-volume demand for both prescription and over-the-counter solutions, and growing local manufacturing capacity. These attributes create opportunities for scalable, low-cost formulations as well as differentiated specialty products targeted at urban centers and digitally enabled patient segments.

Across all regions, local epidemiology, cultural perceptions of women's health, and access to primary care shape uptake. Consequently, regional strategies should align regulatory engagement, distribution partnerships, and patient education initiatives with local healthcare delivery realities to maximize clinical impact and commercial viability.

Competitive dynamics and corporate imperatives for manufacturers, innovators, and distributors competing in the evolving vaginitis therapeutics ecosystem

Competitive positioning in vaginitis therapeutics now hinges on a blend of clinical differentiation, formulation innovation, and distribution agility. Incumbent manufacturers that maintain broad product portfolios often leverage scale to secure channel placement and rapid replenishment, while smaller innovators typically compete on clinical differentiation, novel mechanisms, or superior tolerability profiles. Strategic imperatives for companies include investing in robust comparative evidence that demonstrates reduced recurrence and meaningful patient-reported outcomes, as well as developing packaging and delivery formats that enhance adherence and consumer discretion.

Collaboration between pharmaceutical developers and digital health firms has emerged as an important axis of competitive advantage, enabling bundled offerings that combine pharmacologic therapy with adherence support, symptom tracking, and remote clinician engagement. Moreover, companies that align product development with regulatory pathways for label expansion or OTC switches can unlock new access channels and broaden patient reach. Operationally, securing resilient manufacturing partnerships and flexible contract manufacturing agreements mitigates risk from supply interruptions and tariff-related cost shifts.

Mergers, licensing deals, and strategic alliances remain viable routes to accelerate capability acquisition, whether that entails gaining access to novel probiotic strains, advanced intravaginal delivery platforms, or regional distribution networks. Ultimately, successful companies will integrate clinical excellence with commercial finesse and operational resilience to navigate a competitive and policy-sensitive environment.

High-impact strategic recommendations for industry leaders to accelerate patient outcomes, optimize portfolios, and secure resilient supply chains in vaginitis care

Industry leaders should adopt a set of pragmatic, implementation-focused actions to translate insights into measurable outcomes across clinical, commercial, and operational domains. First, prioritize development pathways that generate head-to-head clinical outcomes and recurrence data, as these endpoints increasingly drive payer and clinician decision-making. Complement clinical programs with patient-centered evidence that captures adherence, quality-of-life metrics, and real-world recurrence prevention to strengthen value propositions.

Second, optimize product portfolios by aligning formulation choices with care settings and patient preferences; for example, invest in discreet intravaginal formats for home treatment, and ensure oral options are supported by clear safety profiles that enable wider primary care adoption. Third, build supply chain resilience through geographic diversification of manufacturing, strategic supplier contracting, and inventory strategies that accommodate tariff volatility and regional demand fluctuations. Fourth, accelerate digital integration by coupling therapies with telehealth-compatible diagnostics and adherence tools, thereby creating stickier patient journeys and enhancing clinical follow-up.

Finally, advance commercial readiness by tailoring distribution strategies across hospital pharmacies, retail points, and online pharmacies, and by developing payer engagement plans that foreground outcomes and economic case narratives. Executed together, these recommendations will help organizations convert scientific and commercial potential into durable clinical impact and market differentiation.

Robust research methodology overview describing data sources, analytical frameworks, validation processes, and limitations underpinning the therapeutic analysis

The research underpinning this report relies on a triangulated methodology that combines primary stakeholder interviews, systematic review of peer-reviewed clinical literature, analysis of regulatory guidelines, and evaluation of distribution and supply chain indicators. Primary inputs include structured interviews with clinicians, formulary managers, procurement leads, and product development experts to capture firsthand perspectives on clinical needs, evidence expectations, and access challenges. Secondary analyses synthesize clinical trial results, guideline updates, and safety profiles to ensure clinical assertions are grounded in the published evidence base.

Data on distribution practices and manufacturing configurations are derived from a combination of public regulatory filings, supply chain disclosures, and industry reports to map typical logistics flows and identify vulnerability points. Analytical frameworks incorporate scenario analysis to evaluate resilience under different trade and policy conditions, as well as cross-segmentation mapping to align product archetypes with distribution channels and end-user cohorts. Validation steps include peer review by subject-matter experts and consistency checks across independent data sources to minimize bias.

Limitations are acknowledged where primary data are constrained or where heterogeneity across regions inhibits universal conclusions. Where appropriate, recommendations are couched in conditional terms and accompanied by suggested next steps for further targeted evidence generation or in-market validation.

Synthesis of strategic insights and closing perspectives that translate clinical, regulatory, and commercial intelligence into executable priorities for stakeholders

The concluding perspective synthesizes clinical, regulatory, and commercial insights into a coherent set of priorities for stakeholders invested in vaginitis therapeutics. Across therapeutic classes and routes of administration, the imperative is clear: therapies that demonstrate meaningful reductions in recurrence, improved tolerability, and alignment with patient preferences are most likely to achieve durable adoption. Implementing this requires an integrated approach that pairs rigorous clinical programs with real-world evidence collection and digital engagement strategies to support adherence and monitoring.

Operational resilience is equally essential; organizations must address supply chain fragility and tariff exposure through diversified sourcing, regional manufacturing options, and strategic inventory management. Commercially, segmentation-informed go-to-market strategies that consider route of administration, product type, distribution channel, and end-user demographics will sharpen targeting and reduce commercial waste. Finally, collaboration across industry, clinical societies, and payer stakeholders can accelerate development of standardized diagnostics and care pathways that benefit patients and streamline adoption.

Taken together, these priorities form a roadmap for translating scientific advances into tangible improvements in patient outcomes while preserving commercial viability in a complex and rapidly evolving environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of next-generation molecular diagnostics for precise vaginal microbiome profiling and treatment targeting
• 5.2. Pipeline emphasis on live biotherapeutic products to restore healthy vaginal flora in recurrent vaginitis patients
• 5.3. Increasing investment in boric acid and non-antibiotic boronate ester therapies for biofilm disruption
• 5.4. Over-the-counter antifungal gel formulations enhanced with mucoadhesive polymers to improve patient adherence and efficacy
• 5.5. Integration of telemedicine and digital symptom tracking apps to personalize vaginitis treatment pathways and outcomes
• 5.6. Personalized therapy selection based on next-generation sequencing of vaginal microbiota and resistance gene profiling
• 5.7. Regulatory approvals accelerating for non-hormonal microbiome restoration products targeting bacterial vaginosis recurrence prevention
• 5.8. Clinical trials evaluating vaginal microbiota transplant efficacy as an alternative approach for refractory bacterial vaginosis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaginitis Therapeutics Market, by Treatment Type

• 8.1. Antifungal Treatments
  • 8.1.1. Azoles
    • 8.1.1.1. Clotrimazole
    • 8.1.1.2. Fluconazole
    • 8.1.1.3. Miconazole
  • 8.1.2. Polyenes
    • 8.1.2.1. Amphotericin B
    • 8.1.2.2. Nystatin
• 8.2. Probiotic Treatments

9. Vaginitis Therapeutics Market, by Route Of Administration

• 9.1. Intravaginal
  • 9.1.1. Creams
  • 9.1.2. Gels
  • 9.1.3. Suppositories
• 9.2. Oral
  • 9.2.1. Capsules
  • 9.2.2. Tablets
• 9.3. Topical
  • 9.3.1. Creams
  • 9.3.2. Gels
  • 9.3.3. Ointments

10. Vaginitis Therapeutics Market, by Product Type

• 10.1. Over The Counter
• 10.2. Prescription

11. Vaginitis Therapeutics Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Vaginitis Therapeutics Market, by End User Demographics

• 12.1. Post-Menopausal Women
  • 12.1.1. Age 46-60
  • 12.1.2. Age 60+
• 12.2. Pre-Menopausal Women
  • 12.2.1. Age 18-25
  • 12.2.2. Age 26-35
  • 12.2.3. Age 36-45
• 12.3. Pregnant Women

13. Vaginitis Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Vaginitis Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Vaginitis Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Pfizer Inc.
  • 16.3.2. The Procter & Gamble Company
  • 16.3.3. Bayer Aktiengesellschaft
  • 16.3.4. Teva Pharmaceutical Industries Ltd.
  • 16.3.5. Viatris Inc.
  • 16.3.6. Dr. Reddy's Laboratories Ltd.
  • 16.3.7. Lupin Limited
  • 16.3.8. Glenmark Pharmaceuticals Ltd.
  • 16.3.9. Cipla Limited
  • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
• TABLE 237. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 238. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 239. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
• TABLE 240. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
• TABLE 241. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 242. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 247. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 248. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 249. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 250. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 251. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 254. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 255. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 256. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 257. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 258. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 259. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 264. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
• TABLE 265. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 266. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 267. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
• TABLE 268. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
• TABLE 269. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 270. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 271. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
• TABLE 272. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
• TABLE 273. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 274. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 275. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 276. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 277. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 280. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 281. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 282. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 283. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 284. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 285. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 286. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 287. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 290. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 291. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 292. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2032 (USD MILLION)
• TABLE 293. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
• TABLE 294. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
• TABLE 295. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
• TABLE 296. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
• TABLE 297. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 298. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 299. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
• TABLE 300. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2032 (USD MILLION)
• TABLE 301. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 302. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 303. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 304. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 305. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 307. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 308. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 309. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 310. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 311. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 312. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 313. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
• TABLE 314. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2032 (USD MILLION)
• TABLE 315. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 316. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 317. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (US